Pierre Laurent‐Puig

69.6k total citations · 11 hit papers
540 papers, 34.6k citations indexed

About

Pierre Laurent‐Puig is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Pierre Laurent‐Puig has authored 540 papers receiving a total of 34.6k indexed citations (citations by other indexed papers that have themselves been cited), including 321 papers in Oncology, 224 papers in Pathology and Forensic Medicine and 155 papers in Cancer Research. Recurrent topics in Pierre Laurent‐Puig's work include Genetic factors in colorectal cancer (214 papers), Colorectal Cancer Treatments and Studies (196 papers) and Cancer Genomics and Diagnostics (131 papers). Pierre Laurent‐Puig is often cited by papers focused on Genetic factors in colorectal cancer (214 papers), Colorectal Cancer Treatments and Studies (196 papers) and Cancer Genomics and Diagnostics (131 papers). Pierre Laurent‐Puig collaborates with scholars based in France, Belgium and Italy. Pierre Laurent‐Puig's co-authors include Hélène Blons, Jessica Zucman‐Rossi, Aurélien de Reyniès, Astrid Lièvre, Bruno Landi, Delphine Le Corre, Jean‐Baptiste Bachet, Valérie Boige, Jean‐François Emile and Gilles Thomas and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Pierre Laurent‐Puig

518 papers receiving 34.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

2001 4.1k citations Pierre Laurent‐Puig et al. profile →
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression

2016 2.2k citations Étienne Becht, Nicolás A. Giraldo et al. profile →
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

2006 1.7k citations Astrid Lièvre, Jean‐Baptiste Bachet et al. Cancer Research profile →
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

2003 1.6k citations Pierre Laurent‐Puig et al. profile →
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

2008 1.1k citations Astrid Lièvre, Jean‐Baptiste Bachet et al. Journal of Clinical Oncology profile →
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

2006 907 citations Aurélien de Reyniès, Emmanuelle Jeannot et al. profile →
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 736 citations Josep Tabernero, Ramón Salazar et al. profile →
Mapping of a susceptibility locus for Crohn's disease on chromosome 16

1996 727 citations Pierre Laurent‐Puig et al. profile →
Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

2009 529 citations Pierre Laurent‐Puig, Anne Cayre et al. Journal of Clinical Oncology profile →
Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

2016 397 citations Étienne Becht, Aurélien de Reyniès et al. Clinical Cancer Research profile →
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

2018 301 citations Yuna Blum, Jérôme Cros et al. profile →

Peers

Countries citing papers authored by Pierre Laurent‐Puig

Since Specialization

Citations

This map shows the geographic impact of Pierre Laurent‐Puig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Laurent‐Puig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Laurent‐Puig more than expected).

Fields of papers citing papers by Pierre Laurent‐Puig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Laurent‐Puig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Laurent‐Puig. The network helps show where Pierre Laurent‐Puig may publish in the future.

Co-authorship network of co-authors of Pierre Laurent‐Puig

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Laurent‐Puig. A scholar is included among the top collaborators of Pierre Laurent‐Puig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Laurent‐Puig. Pierre Laurent‐Puig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer 2023 ·Cancers ·(unknown), Ken Op de Beeck, Pierre Laurent‐Puig, Valérie Taly, Léonor Benhaïm	12
2	Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy 2021 ·Cancer Research ·Carla Frau, Catherine Jamard, (unknown), Gabriela D. A. Guardia, Christelle Machon, Camilla Pilati, (unknown), Pierre Laurent‐Puig, Jérôme Guitton, Pedro A. F. Galante, Luiz O. F. Penalva, Jean‐Noël Freund, Christelle de la Fouchardière, Michelina Plateroti	6
3	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer 2021 ·Clinical Cancer Research ·Laëtitia Marisa, Yuna Blum, Julien Taı̈eb, Mira Ayadi, Camilla Pilati, Karine Le Malicot, Côme Lepage, Ramón Salazar, Daniela Aust, Alex Duval, Hélène Blons, Valérie Taly, David Gentien, Audrey Rapinat, Janick Sèlves, Sophie Mouillet‐Richard, Valérie Boige, Jean‐François Emile, Aurélien de Reyniès, Pierre Laurent‐Puig	37
4	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial 2021 ·Clinical Cancer Research ·Julien Taı̈eb, Valérie Taly, Julie Henriques, (unknown), Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Christophe Louvet, Céline Lepère, May Mabro, Joëlle Egreteau, Olivier Bouché, Claire Mulot, (unknown), Kariman Chaba, Thibault Mazard, Aimery de Gramont, Déwi Vernerey, Thierry André, Pierre Laurent‐Puig	71
5	Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma 2020 ·Clinical Cancer Research ·Jean‐Baptiste Bachet, Hélène Blons, Pascal Hammel, (unknown), Fabienne Portales, Laurent Mineur, Jean‐Philippe Metges, Claire Mulot, (unknown), Jason E. Cain, Jérôme Cros, Pierre Laurent‐Puig	31
6	TP53, STK11 , and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma 2018 ·Clinical Cancer Research ·Jérôme Biton, Audrey Mansuet‐Lupo, Nicolas Pécuchet, Marco Alifano, Hanane Ouakrim, Jennifer Arrondeau, Pascaline Boudou‐Rouquette, François Goldwasser, Karen Leroy, Jérémy Goc, Marie Wislez, Claire Germain, Pierre Laurent‐Puig, Marie‐Caroline Dieu‐Nosjean, Isabelle Cremer, Ronald Herbst, Hélène Blons, Diane Damotte	251
7	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy 2018 ·Clinical Cancer Research ·Claire Gallois, Julien Taı̈eb, Delphine Le Corre, Karine Le Malicot, Josep Tabernero, Claire Mulot, Jean‐François Seitz, Thomas Aparicio, Gunnar Folprecht, Côme Lepage, Enrico Mini, Jean‐Luc Van Laethem, Jean‐François Emile, Pierre Laurent‐Puig	24
8	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer 2018 ·Clinical Cancer Research ·Pierre Laurent‐Puig, (unknown), Volker Heinemann, (unknown), Daniel Neureiter, Andreas Jung, François Montestruc, Yann Gaston‐Mathé, Raphaële Thiébaut, Sebastian Stintzing	31
9	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) 2017 ·Clinical Cancer Research ·Fanny Garlan, Pierre Laurent‐Puig, David Sefrioui, Nathalie Siauve, Audrey Didelot, Nasrin Sarafan‐Vasseur, Pierre Michel, Géraldine Perkins, Claire Mulot, Hélène Blons, Julien Taı̈eb, Frédéric Di Fiore, Valérie Taly, Aziz Zaanan	165
10	Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker 2016 ·Clinical Cancer Research ·Daniel Pietrasz, Nicolas Pécuchet, Fanny Garlan, Audrey Didelot, Olivier Dubreuil, Solène Doat, Françoise Imbert‐Bismut, Mehdi Karoui, Jean‐Christophe Vaillant, Valérie Taly, Pierre Laurent‐Puig, Jean‐Baptiste Bachet	183
11	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy breakdown → 2016 ·Clinical Cancer Research ·Étienne Becht, Aurélien de Reyniès, Nicolás A. Giraldo, Camilla Pilati, Bénédicte Buttard, Laetitia Lacroix, Janick Sèlves, Catherine Sautès‐Fridman, Pierre Laurent‐Puig, Wolf H. Fridman	397
12	A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy 2014 ·Clinical Cancer Research ·Zenia Saridaki, Joanne B. Weidhaas, Heinz‐Josef Lenz, Pierre Laurent‐Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, Sabine Tejpar	52
13	Clinical Relevance of KRAS -Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy 2014 ·Clinical Cancer Research ·Pierre Laurent‐Puig, Deniz Pekin, Corinne Normand, Steve K. Kotsopoulos, Philippe Nizard, Karla Perez‐Toralla, R. Kevin Rowell, Jeff Olson, Preethi Srinivasan, Delphine Le Corre, (unknown), (unknown), Xinyu Li, Darren R. Link, Olivier Bouché, Jean‐François Emile, Bruno Landi, Valérie Boige, J. Brian Hutchison, Valérie Taly	118
14	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients 2013 ·Clinical Cancer Research ·Justin Guinney, Charles Ferté, Jonathan R. Dry, Robert McEwen, Gilles Manceau, (unknown), Kai‐Ming Chang, Claus Bendtsen, Kevin Hudson, Erich Huang, Brian Dougherty, Michel Ducreux, Jean‐Charles Soria, Stephen Friend, Jonathan M.J. Derry, Pierre Laurent‐Puig	30
15	Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer breakdown → 2009 ·Journal of Clinical Oncology ·Pierre Laurent‐Puig, Anne Cayre, Gilles Manceau, Emmanuel Buc, Jean‐Baptiste Bachet, Thierry Lecomte, Philippe Rougier, Astrid Lièvre, Bruno Landi, Valérie Boige, Michel Ducreux, Marc Ychou, Frédéric Bibeau, Olivier Bouché, Julia Reid, Steven Stone, Frédérique Penault‐Llorca	529
16	Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases 2008 ·Cancer Research ·Ludovic Barault, Céline Charon‐Barra, Valérie Jooste, Mathilde Funes de la Vega, Laurent Martin, Patrick Roignot, Patrick Rat, Anne‐Marie Bouvier, Pierre Laurent‐Puig, Jean Faivre, Caroline Chapusot, F Piard	239
17	The Soluble α Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer 2008 ·Cancer Research ·Cécile Badoual, Grégory Bouchaud, Nour El Houda Agueznay, Erwan Mortier, Stéphane Hans, Alain Gey, (unknown), Séverine Peyrard, Pierre Laurent‐Puig, P Bruneval, Xavier Sastre, Ariane Plet, Laure Garrigue‐Antar, Françoise Quintin‐Colonna, Wolf H. Fridman, Daniel Brasnu, Yannick Jacques, Éric Tartour	73
18	KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab breakdown → 2008 ·Journal of Clinical Oncology ·Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige, Anne Cayre, Delphine Le Corre, Emmanuel Buc, Marc Ychou, Olivier Bouché, Bruno Landi, Christophe Louvet, Thierry André, Frédéric Bibeau, Marie-Danièle Diébold, Philippe Rougier, Michel Ducreux, Gorana Tomasic, Jean‐François Emile, Frédérique Penault–Llorca, Pierre Laurent‐Puig	1141
19	Association of CYP1B1 Germ Line Mutations with Hepatocyte Nuclear Factor 1α–Mutated Hepatocellular Adenoma 2007 ·Cancer Research ·Emmanuelle Jeannot, Karine Poussin, L. Chiche, Yannick Bacq, Nathalie Stürm, Jean‐Yves Scoazec, Catherine Buffet, Jeanne Tran Van Nhieu, Christine Bellanné‐Chantelot, Claudia de Toma, Pierre Laurent‐Puig, Paulette Bioulac‐Sage, Jessica Zucman‐Rossi	47
20	Identification of the IFITM Family as a New Molecular Marker in Human Colorectal Tumors 2006 ·Cancer Research ·Pauline Andreu, Sabine Colnot, Cécile Godard, Pierre Laurent‐Puig, Dominique Lamarque, Axel Kahn, Christine Perret, Béatrice Romagnolo	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact